DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis
Samih H. Nasr(Mayo Clinic), Mariam P. Alexander(University of Minnesota Rochester), Loren P. Herrera Hernandez(Mayo Clinic), Nathalie Quellard(Université de Poitiers), John C. Lieske(Mayo Clinic), Samar M. Said(Mayo Clinic), Ellen D. McPhail(Mayo Clinic), Joseph P. Grande(Mayo Clinic), Surendra Dasari(Mayo Clinic in Arizona), Nelson Leung(WinnMed), Sanjeev Sethi(Mayo Clinic), Fernando C. Fervenza(Mayo Clinic), Paul J. Kurtin(Mayo Clinic), Alexia Rinsant(Université de Poitiers), Lynn D. Cornell(University of Calgary), Marie C. Hogan(Mayo Clinic), Frank Bridoux(Université de Poitiers), Julie A. Vrana(Mayo Clinic), Jean Michel Goujon(Université de Poitiers), Mary E. Fidler(Mayo Clinic), Sihem Kaaki(Université de Poitiers)
Cited by 168
Related Papers
The Banff 97 working classification of renal allograft pathology
|Kidney International|1999|3.1k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
|American Journal of Transplantation|2014|1.3k
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification
|Kidney International|2009|1.2k
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility
|Kidney International|2009|1k